10X GENOMICS INC

Member Only Articles

AI Health Factor Performance Trends

Latest Insights

17 February, 2025
10x Genomics Reports Decline in Q4 Revenues and Projects Stagnant Growth Amid NIH Funding Cap Concerns
Read More >>
16 February, 2025
10x Genomics Reports Decline in Q4 Revenues and Projects Stagnant Growth Amid NIH Funding Cap Concerns
10x Genomics, Inc. (NASDAQ: TXG) recently held its Q4 2024 earnings conference call on February 12, 2025, where CEO Serge Saxonov and executives discussed the company's performance for the fourth quar...
Read More
15 February, 2025
10x Genomics Reports Decline in Q4 Revenues Amid NIH Funding Concerns and Projects Modest Growth for 2025
10x Genomics, Inc. (NASDAQ: TXG) recently held its Q4 2024 earnings conference call on February 12, 2025, revealing significant insights into the company's financial status. CEO Serge Saxonov reported...
Read More
14 February, 2025
10x Genomics Projects Minimal Growth Ahead Amid NIH Funding Concerns and Declining Revenues
10x Genomics has projected revenues between $610 million and $630 million for 2025, reflecting minimal growth amid significant uncertainties, particularly due to a potential cap on NIH funding. In its...
Read More
12 February, 2025
10x Genomics Faces Stock Volatility Amid NIH Funding Cap Announcement, While Ark Invest Boosts Its Stake in the Company
10x Genomics has recently been under pressure following a 13% to 15% drop in stock price, triggered by the National Institutes of Health (NIH) announcing a cap on indirect expenses related to medical ...
Read More

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.